Treatment of TB

European Respiratory Monograph

Volumn 58, Issue , 2012, Pages 154-166

  Caminero, Jose A ^a,b   Matteelli, Alberto ^c   Lange, Christoph ^d,e,f  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b International Union against Tuberculosis and Lung Disease   (France)

^c UNIVERSITY OF BRESCIA   (Italy)

^d Division of Clinical Infectious Diseases   (Germany)

^e RESEARCH CENTER BORSTEL   (Germany)

^f UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anti tuberculosis drugs; Extensively drugresistant tuberculosis; Multidrug resistant; Multidrug resistant tuberculosis; Treatment; Tuberculosis

Indexed keywords

EID: 84870949052     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10023511     Document Type: Article

References (49)

1. Grzybowski S, Enarson DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis 1978; 53: 70-75.
2. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279.
3. Caminero Luna JA. A tuberculosis guide for specialist physicians. Paris, International Union Against Tuberculosis and Lung Disease, 2004.
4. Mitchison DA. Microbial genetics and chemotherapy. Br Med Bull 1962; 18: 74-80.
5. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: 771-781.
6. Van Deun A, Kya Jai Maug A, Halim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
7. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
8. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
9. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: randomised clinical trial. Lancet 2002; 360: 528-534.
10. Mitchison DA, Dickinson JM. Laboratory aspects of intermittent drug therapy. Postgrad Med J 1971; 47: 737-741.
11. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
12. Chang KC, Leung CC, Grosset J, et al. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: 997-1007.
13. Fuentes ZM, Caminero JA. Controversies in the treatment of extrapulmonary tuberculosis. Arch Bronconeumol 2006; 42: 194-201.
14. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th Edn. World Health Organization Document 2010;WHO/HTM/TB/2009.420:1-147. Geneva, World Health Organization, 2010.
15. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
16. van Loenhout-Rooyackers JH, Keyser A, Laheij RJF, et al. Tuberculous meningitis: is a 6-month treatment regimen sufficient? Int J Tuberc Lung Dis 2001; 5: 1028-1035.
17. Jacobs RF, Sunakorn P, Chotpitayasunondh T, et al. Intensive short course chemotherapy for tuberculous meningitis. Pediatr Infect Dis J 1992; 11: 194-198.
18. Caminero JA, Fuentes ZM, Martín TY, et al. A 6-month regimen for EPTB with intermittent treatment in the continuation phase: a study of 679 cases. Int J Tuberc Lung Dis 2005; 9: 890-895.
19. Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thorcic Society, CDC, and Infectious Diseases Society of America. Morb Mortal Wkly Rep 2003; 52: 1-80.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. World Health Organization Document 2008; WHO/HTM/TB/2008.402:1-247. Geneva, World Health Organization, 2008.
21. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
22. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
23. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837.
24. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569.
25. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-140.
26. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.
27. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
28. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drugresistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
29. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. World Health Organization Document 2011;WHO/HTM/TB/2011.6:1-33. Geneva, World Health Organization, 2011.
30. Jordan TS, Cullen D, Davies PD. A centralised electronic Multidrug-Resistant Tuberculosis Advisory Service: the first 2 years. Int J Tuberc Lung Dis 2012; 16: 950-954.
31. Erkens CGM, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigations in low prevalence countries: a European consensus. Eur Respir J 2010; 36: 925-949.
32. Ma Z, Lienhardt C. Toward optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med 2009; 30: 755-768.
33. Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and reality. Lancet 2010; 375: 2100-2109.
34. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170: 1131-1134.
35. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426.
36. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
37. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338.
38. Migliori GB, Eker B, Richardson MD, et al. A retrospectve TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
39. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis 2007; 11: 606-611.
40. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; [Epub ahead of print DOI: 10.1183/09031936.00022912].
41. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrugresistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
42. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.
43. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-966.
44. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smearpositive tuberculosis patients. Antimicrob Agents Chemother 2010; 54: 3402-3407.
45. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
46. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
47. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
48. Burman WJ. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis 2010; 50: Suppl. 3, S165-S172.
49. Monedero I, Caminero JA. Management of multidrug-resistant tuberculosis: an update. Ther Adv Respir Dis 2010; 4: 117-127.